Apalutamide and autophagy inhibition in a xenograft mouse model of human prostate cancer
Authors:
Open Access
- 25 June 2022
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 148 (12) , 3351-3360
Abstract
Background: Apalutamide (APA) is a next-generation androgen receptor antagonist for the treatment of advanced prostate cancer. We have previously shown that upregulation of autophagy is one of the mechanisms by which prostate cancer (PC) cells survive APA anti-tumor treatment in vitro. Therefore, we investigated the characteristics of the autophagic response to APA treatment, alone and in combination with autophagy inhibition, in an in vivo model. Methods: Tumor cells were injected into previously castrated nude mice. Four groups of mice bearing LNCaP xenografts were treated with daily intraperitoneal (i.p.) injections of vehicle (control), APA (10 mg/kg), APA (10 mg/kg) + Chl (Chloroquine, 10 mg/kg) or Chl (10 mg/kg). The animals of each treatment group (3/treatment) were kept for the duration of 2 and 3 weeks. At the end of the experiments, the animals were sacrificed and all samples assessed for tumor weight and size, histological analysis, immunoblotting (WES) and immunofluorescence. Results: The tumor weight was significantly reduced in mice treated with APA + Chl (203.2 ± 5.0, SEM, P = 0.0066) compared to vehicle control (380.4 ± 37.0). Importantly, the combined treatment showed a higher impact on tumor weight than APA (320.4 ± 45.5) or Chl (337.9 ± 35) alone. The mice treated with the combination of APA + Chl exhibited a reduced expression of ATG5 (autophagy-related five protein), Beclin 1 and LC3 punctuations and an increase in P62 as visualized by immunofluorescence and WES. In addition, Ki-67 nuclear staining was detected in all samples however reduced in APA + Chl (58%) compared to vehicle control (100%). The reduction in Ki-67 protein was associated with an increase in caspase 3 and endothelial CD31 protein expression. Conclusion: These data demonstrate that a treatment with APA + Chl leads to reduced autophagy levels and to tumor suppression compared to the APA monotherapy. Hence, the increased antitumor effect of APA in combination with autophagy inhibitors might provide a new therapeutic approach potentially translatable to patients.Keywords
Funding Information
- Janssen Pharmaceutical NV
- Stiftung zur Krebsbekämpfung
- University of Zurich
This publication has 33 references indexed in Scilit:
- Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone‐resistant prostate cancer cells and confer resistance to apoptosisThe Prostate, 2013
- ARN-509: A Novel Antiandrogen for Prostate Cancer TreatmentCancer Research, 2012
- Effect of dual inhibition of apoptosis and autophagy in prostate cancerThe Prostate, 2012
- Autophagy: Renovation of Cells and TissuesCell, 2011
- Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase InhibitorsGenes & Cancer, 2010
- Blocked Autophagy Sensitizes Resistant Carcinoma Cells to Radiation TherapyCancer Research, 2008
- Potential therapeutic applications of autophagyNature Reviews Drug Discovery, 2007
- Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphomaJournal of Clinical Investigation, 2007
- Secondary Hormonal Therapy for Advanced Prostate CancerJournal of Urology, 2006
- p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell deathJournal of Cell Biology, 2005